Study Shows Businesses Selling Unapproved Stem Cell Treatments Have Turned to Long COVID.
JAMA
; 330(24): 2326-2327, 2023 12 26.
Article
em En
| MEDLINE
| ID: mdl-38019493
This Medical News article discusses a new study that identified how business have pivoted marketing of unapproved stem cell and exosome products from COVID-19 to long COVID.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Aprovação de Drogas
/
Transplante de Células-Tronco
/
Síndrome de COVID-19 Pós-Aguda
Limite:
Humans
Idioma:
En
Revista:
JAMA
Ano de publicação:
2023
Tipo de documento:
Article